SCHEMBL9909937

SCHEMBL9909937

CC(C)(C)OC(=O)Nc1ccc(-n2nccn2)nc1

nearest known ligand 0.52

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
NAMPT P43490 1/20 0.49
CYP17A1 P05093 3/20 0.45
MALT1 Q9UDY8 1/20 0.41
MAPKAPK2 P49137 3/20 0.41
PSMB8 P28062 1/20 0.41
MAP4K4 O95819 1/20 0.40
HDAC3 O15379 1/20 0.40
HDAC8 Q9BY41 1/20 0.40
NCOR2 Q9Y618 1/20 0.40
BCL2 P10415 1/20 0.40
ATR Q13535 1/20 0.40
ALDH1A1 P00352 1/20 0.39
MAPT P10636 1/20 0.39
EGLN2 Q96KS0 1/20 0.39
WNT3A P56704 1/20 0.39
GSK3B P49841 1/20 0.38
DYRK1A Q13627 1/20 0.38
TRPV1 Q8NER1 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9909935 0.81 NAMPT (0.42) NAMPTCYP17A1MAPKAPK2PSMB8MAP4K4
SCHEMBL9909932 0.80 LMNA (0.53) NAMPTCYP17A1MAP4K4ALDH1A1MAPT
SCHEMBL1984304 0.79 TRPV1 (0.57) NAMPTALDH1A1MAPTWNT3ATRPV1
SCHEMBL23032846 0.77 MALT1 (0.45) NAMPTCYP17A1MALT1EGLN2GSK3B
SCHEMBL29929054 0.77 P4HTM (0.54) NAMPTCYP17A1
SCHEMBL1734048 0.77 P4HTM (0.54) NAMPTCYP17A1
SCHEMBL29301634 0.77 MAPT (0.61) MAPTWNT3A
SCHEMBL9909933 0.77 KCNJ1 (0.53) NAMPTCYP17A1BCL2
SCHEMBL376258 0.77 NAMPT (0.56) NAMPTCYP17A1MAPKAPK2PSMB8MAP4K4
SCHEMBL6609814 0.77 NAMPT (0.52) NAMPTCYP17A1MAPKAPK2PSMB8MAP4K4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2464228-B1 SUBSTITUTED CYCLOPROPYL COMPOUNDS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT MERCK SHARP & DOHME (US) 2017-12-06 EP disclosed
US-20120142706-A1 SUBSTITUTED CYCLOPROPYL COMPOUNDS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT MERCK SHARP & DOHME LLC 2012-06-07 US disclosed
WO-2011019538-A1 SUBSTITUTED CYCLOPROPYL COMPOUNDS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT MERCK SHARP & DOHME CORP. (US) 2011-02-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120142706-A1 SUBSTITUTED CYCLOPROPYL COMPOUNDS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT GPR119, GPR27, GCGR NAMPT 2670/4885CYP17A1 875/4885MALT1 3005/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.